Your browser doesn't support javascript.
loading
Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
Chong, Elise A; Kumashie, Kingsley Gideon; Chong, Emeline R; Fabrizio, Joseph; Gupta, Aditi; Svoboda, Jakub; Barta, Stefan K; Walsh, Kristy M; Napier, Ellen B; Lundberg, Rachel K; Nasta, Sunita D; Gerson, James N; Landsburg, Daniel J; Gonzalez, Joyce; Gaano, Andrew; Weirick, Madison E; McAllister, Christopher M; Awofolaju, Moses; John, Gavin N; Kammerman, Shane C; Novaceck, Josef; Pajarillo, Raymone; Lundgreen, Kendall A; Tanenbaum, Nicole; Gouma, Sigrid; Drapeau, Elizabeth M; Adamski, Sharon; D'Andrea, Kurt; Pattekar, Ajinkya; Hicks, Amanda; Korte, Scott; Sharma, Harsh; Herring, Sarah; Williams, Justine C; Hamilton, Jacob T; Bates, Paul; Hensley, Scott E; Prak, Eline T Luning; Greenplate, Allison R; Wherry, E John; Schuster, Stephen J; Ruella, Marco; Vella, Laura A.
Afiliação
  • Chong EA; The Richard Berman Family Innovations Center in CLL and Lymphomas, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Kumashie KG; Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Chong ER; Division of Infectious Diseases, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Fabrizio J; The Richard Berman Family Innovations Center in CLL and Lymphomas, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Gupta A; The Richard Berman Family Innovations Center in CLL and Lymphomas, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Svoboda J; Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Barta SK; The Richard Berman Family Innovations Center in CLL and Lymphomas, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Walsh KM; Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Napier EB; The Richard Berman Family Innovations Center in CLL and Lymphomas, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Lundberg RK; Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Nasta SD; The Richard Berman Family Innovations Center in CLL and Lymphomas, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Gerson JN; The Richard Berman Family Innovations Center in CLL and Lymphomas, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Landsburg DJ; The Richard Berman Family Innovations Center in CLL and Lymphomas, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Gonzalez J; The Richard Berman Family Innovations Center in CLL and Lymphomas, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Gaano A; Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Weirick ME; The Richard Berman Family Innovations Center in CLL and Lymphomas, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • McAllister CM; Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Awofolaju M; The Richard Berman Family Innovations Center in CLL and Lymphomas, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • John GN; Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Kammerman SC; Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Novaceck J; Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Pajarillo R; Department of Microbiology, University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Lundgreen KA; Department of Microbiology, University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Tanenbaum N; Department of Microbiology, University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Gouma S; Division of Infectious Diseases, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Drapeau EM; Division of Infectious Diseases, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Adamski S; Division of Infectious Diseases, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • D'Andrea K; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Pattekar A; Department of Microbiology, University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Hicks A; Department of Microbiology, University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Korte S; Department of Microbiology, University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Sharma H; Department of Microbiology, University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Herring S; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Williams JC; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Hamilton JT; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Bates P; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Hensley SE; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Prak ETL; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Greenplate AR; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Wherry EJ; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Schuster SJ; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Ruella M; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Vella LA; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
J Infect Dis ; 2024 Mar 04.
Article em En | MEDLINE | ID: mdl-38437622
ABSTRACT
Patients with B-cell lymphomas have altered cellular components of vaccine responses due to malignancy and therapy, and the optimal timing of vaccination relative to therapy remains unknown. SARS-CoV-2 vaccines created an opportunity for new insights in vaccine timing because patients were challenged with a novel antigen across multiple phases of treatment. We studied serologic mRNA vaccine response in retrospective and prospective cohorts with lymphoma and CLL, paired with clinical and research immune parameters. Reduced serologic response was observed more frequently during active therapies, but non-response was also common within observation and post-treatment groups. Total IgA and IgM correlated with successful vaccine response. In individuals treated with CART-19, non-response was associated with reduced B and T follicular helper cells. Predictors of vaccine response varied by disease and therapeutic group, and therefore further studies of immune health during and after cancer therapies are needed to allow individualized vaccine timing.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos